134 related articles for article (PubMed ID: 16818279)
1. Heterogeneous expression of CD32 and CD32-mediated growth suppression in human myeloma cells.
Zheng X; Abroun S; Otsuyama K; Asaoku H; Kawano MM
Haematologica; 2006 Jul; 91(7):920-8. PubMed ID: 16818279
[TBL] [Abstract][Full Text] [Related]
2. CD32-mediated suppression of plasma cells in patients with multiple myeloma.
Ross B
Haematologica; 2006 Jul; 91(7):869A. PubMed ID: 16818269
[No Abstract] [Full Text] [Related]
3. CD74 is expressed by multiple myeloma and is a promising target for therapy.
Burton JD; Ely S; Reddy PK; Stein R; Gold DV; Cardillo TM; Goldenberg DM
Clin Cancer Res; 2004 Oct; 10(19):6606-11. PubMed ID: 15475450
[TBL] [Abstract][Full Text] [Related]
4. MPC-1-CD49e- immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas.
Fujii R; Ishikawa H; Mahmoud MS; Asaoku H; Kawano MM
Br J Haematol; 1999 Apr; 105(1):131-40. PubMed ID: 10233376
[TBL] [Abstract][Full Text] [Related]
5. [Phenotypic analysis of myeloma cells].
Mihara K; Harada H; Kawano MM
Nihon Rinsho; 1995 Mar; 53(3):574-9. PubMed ID: 7699888
[TBL] [Abstract][Full Text] [Related]
6. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia.
Horton HM; Bernett MJ; Pong E; Peipp M; Karki S; Chu SY; Richards JO; Vostiar I; Joyce PF; Repp R; Desjarlais JR; Zhukovsky EA
Cancer Res; 2008 Oct; 68(19):8049-57. PubMed ID: 18829563
[TBL] [Abstract][Full Text] [Related]
7. [The abnormality of FcgammaRIIB1-mediated signaling and the hyperactivity of B cells from patients with systemic lupus erythematosus].
Peng KJ; Xiao LS; Fei Y; Wang SR
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2006 Nov; 22(6):769-71. PubMed ID: 17077019
[TBL] [Abstract][Full Text] [Related]
8. Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16).
Bruenke J; Barbin K; Kunert S; Lang P; Pfeiffer M; Stieglmaier K; Niethammer D; Stockmeyer B; Peipp M; Repp R; Valerius T; Fey GH
Br J Haematol; 2005 Jul; 130(2):218-28. PubMed ID: 16029450
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.
Santonocito AM; Consoli U; Bagnato S; Milone G; Palumbo GA; Di Raimondo F; Stagno F; Guglielmo P; Giustolisi R
Leuk Res; 2004 May; 28(5):469-77. PubMed ID: 15068900
[TBL] [Abstract][Full Text] [Related]
10. Lactate dehydrogenase production and release in a newly established human myeloma cell line.
Hatakeyama N; Daibata M; Nemoto Y; Ohtsuki Y; Taguchi H
Am J Hematol; 2001 Apr; 66(4):267-73. PubMed ID: 11279638
[TBL] [Abstract][Full Text] [Related]
11. CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.
Kim D; Park CY; Medeiros BC; Weissman IL
Leukemia; 2012 Dec; 26(12):2530-7. PubMed ID: 22733078
[TBL] [Abstract][Full Text] [Related]
12. The phenotype of normal, reactive and malignant plasma cells. Identification of "many and multiple myelomas" and of new targets for myeloma therapy.
Bataille R; Jégo G; Robillard N; Barillé-Nion S; Harousseau JL; Moreau P; Amiot M; Pellat-Deceunynck C
Haematologica; 2006 Sep; 91(9):1234-40. PubMed ID: 16956823
[TBL] [Abstract][Full Text] [Related]
13. Correlation between serum levels of free light chain and phenotype of plasma cells in bone marrow in primary AL amyloidosis.
Shimojima Y; Matsuda M; Gono T; Ishii W; Fushimi T; Hoshii Y; Yamada T; Ikeda S
Amyloid; 2005 Mar; 12(1):33-40. PubMed ID: 16076609
[TBL] [Abstract][Full Text] [Related]
14. IGG and complement receptor expression on peripheral white blood cells in uraemic children.
Bouts AH; Krediet RT; Davin JC; Monnens LA; Nauta J; Schröder CH; van de Winkel JG; Out TA
Nephrol Dial Transplant; 2004 Sep; 19(9):2296-301. PubMed ID: 15266033
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies capable of discriminating the human inhibitory Fcgamma-receptor IIB (CD32B) from the activating Fcgamma-receptor IIA (CD32A): biochemical, biological and functional characterization.
Veri MC; Gorlatov S; Li H; Burke S; Johnson S; Stavenhagen J; Stein KE; Bonvini E; Koenig S
Immunology; 2007 Jul; 121(3):392-404. PubMed ID: 17386079
[TBL] [Abstract][Full Text] [Related]
16. Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells.
Suzuki T; Coustan-Smith E; Mihara K; Campana D
Leukemia; 2002 Jul; 16(7):1276-84. PubMed ID: 12094251
[TBL] [Abstract][Full Text] [Related]
17. [Detection of multiple myeloma cells using multicolor immunofluorescence and flow cytometry].
Tousková M; Maisnar V; Krejsek J; Kopecký O
Vnitr Lek; 1999 Dec; 45(12):708-12. PubMed ID: 10951845
[TBL] [Abstract][Full Text] [Related]
18. Expression of c-Kit isoforms in multiple myeloma: differences in signaling and drug sensitivity.
Montero JC; López-Pérez R; San Miguel JF; Pandiella A
Haematologica; 2008 Jun; 93(6):851-9. PubMed ID: 18443272
[TBL] [Abstract][Full Text] [Related]
19. CD19 expression and growth inhibition of tumours in human multiple myeloma.
Ishikawa H; Tsuyama N; Mahmoud MS; Fujii R; Abroun S; Liu S; Li FJ; Kawano MM
Leuk Lymphoma; 2002 Mar; 43(3):613-6. PubMed ID: 12002767
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of vascular endothelial growth factors and their receptors in multiple myeloma.
Kimlinger T; Kline M; Kumar S; Lust J; Witzig T; Rajkumar SV
Haematologica; 2006 Aug; 91(8):1033-40. PubMed ID: 16870555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
